Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$5.3 billion.

  • Gsk's Operating Expenses rose 2244.92% to -$5.3 billion in Q3 2025 from the same period last year, while for Dec 2025 it was -$15.3 billion, marking a year-over-year increase of 6038.54%. This contributed to the annual value of $22.3 billion for FY2024, which is 1467.45% up from last year.
  • Latest data reveals that Gsk reported Operating Expenses of -$5.3 billion as of Q3 2025, which was up 2244.92% from -$5.6 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Operating Expenses ranged from a high of -$3.5 billion in Q1 2021 and a low of -$22.4 billion during Q4 2024
  • In the last 5 years, Gsk's Operating Expenses had a median value of -$4.5 billion in 2023 and averaged -$7.3 billion.
  • As far as peak fluctuations go, Gsk's Operating Expenses skyrocketed by 3329.51% in 2021, and later crashed by 4278.75% in 2022.
  • Quarter analysis of 5 years shows Gsk's Operating Expenses stood at -$11.4 billion in 2021, then crashed by 42.79% to -$16.3 billion in 2022, then dropped by 19.16% to -$19.4 billion in 2023, then decreased by 15.39% to -$22.4 billion in 2024, then surged by 76.29% to -$5.3 billion in 2025.
  • Its Operating Expenses was -$5.3 billion in Q3 2025, compared to -$5.6 billion in Q2 2025 and -$4.4 billion in Q1 2025.